Rethinking breast cancer follow-up based on individual risk and recurrence management

Breast cancer is the most common cancer in women in the world and remains a major public health burden with 25% of all cancer cases and 15% of all cancer deaths among females [1]. Incidence increased with the introduction of mammography screening and continues to grow, mainly due to population ageing; meanwhile, breast cancer survival has significantly improved over the past decades [2]. Ten-year cancer specific survival exceeds 70%, with 89% survival for local and 62% for regional disease [2]. The risk of recurrence of patients diagnosed with hormonal receptor (HR)-negative breast cancer is high during the first two years after the initial diagnosis, but rapidly drops thereafter below that of HR-positive tumors [3].

Source: Cancer Treatment Reviews - June 30, 2022 Category: Cancer & Oncology Authors: Fiorenza De Rose, Bruno Meduri, Maria Carmen De Santis, Antonella Ferro, Lorenza Marino, Riccardo Ray Colciago, Fabiana Gregucci, Valentina Vanoni, Giovanni Apolone, Serena Di Cosimo, Suzette Delaloge, Javier Cortes, Giuseppe Curigliano Source Type: research